Brought to you by 
PPD nets $1.5bn in IPO
Feb 2020
Executive Summary
PPD Inc., a PE-owned contract research organization (CRO), netted $1.5B in its initial public offering of 60M shares at $27, the high end of its anticipated $24-27 range.
Deal Industry
- Biotechnology
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
- Services
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PPD nets $1.5bn in IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice